Downloads
Article: Cell Cultivation Process Transfer And Scale-Up
By T.C. Seamans, S. Fries, A. Beck, T. Wurch, S. Chenu, C. Chan, M. Ushio, J. Bailey, A. Kejariwal, C. Ranucci, N. Villani, S. Ozuna, L. Goetsch, N. Corvaia, P. Salmon, D. Robinson, and M. Chartrain
The introduction of therapeutic monoclonal antibodies (MAbs) has greatly revolutionized therapies for several cancer types and immune disorders. Benefits to patients have been substantial, translating into both increased life expectancy and improved quality of life. Currently, twenty-one therapeutic MAbs are registered for marketing in the United States, with the introduction of several more expected in the coming years.
Reprinted with permission from BioProcess International
The content you requested is only available to registered users of Bioresearch Online. By registering now, you'll get access to this piece of content and thousands of additional articles and product reviews across our entire network of sites.
